The rheuma Twitterverse was having a field day over at the ACR conference in Atlanta last week. Here are the highlights
The rheuma Twitterverse was having a field day over at the ACR conference in Atlanta last week. Here are the highlights:
10
?Are you looking ? for a visual summary ? of the main #clinicaltrials (and their #targets ? & #outcomes) for the #treatment ? of systemic #lupus presented at #ACR19? #SLE?
Well…here it is! pic.twitter.com/kx1EE3zCXq— Laurent ARNAUD (@Lupusreference) November 14, 2019
9
Hello #ACR19. Are you still confused ? about the #pathways of #JAK-inhibitors and #Interferon-blocking strategies in #Lupus? Check up this refresher slide showing what these #SLE #treatments target!! ? pic.twitter.com/ZNnJTkz4nK
— Laurent ARNAUD (@Lupusreference) November 12, 2019
8
#ACR2019 #acr19 new Guidelines OA:
?exercise (aerobic/streng/neuroM/aquatic?)
???weigth???
✅tai chi
?TENS?(no evidence)
✅topical/oral NDSAIDs/intraarticular GCs
?intraarticular HyA (hip)?
?glucosamine and/or chondroitin?
(Look slides ??) pic.twitter.com/Y76IECqkPJ— ?????? ??????-?ℎ????? (@MerayoDr) November 13, 2019
7
Immune-mediated causes of uveitis
• Behcet’s disease
• Cogan’s syndrome
• IBD
• TINU
• JIA
• Multiple sclerosis
• Psoriatic arthritis/ AS/ Reactive Arthritis
• Relapsing polychondritis
• Sarcoidosis
• SLE
• Vasculitis
• Vogt-Koyanagi-Harada Syndrome#ACR19 @RheumNow— Kanika Monga, MD (@DrKanikaMonga) November 13, 2019
6
Ladies of #Rheumatology, the numbers are in. I am proud to report that 49.1% of presenters and moderators at #ACR19 will be women… for #ACR20 I am counting on you all to help us #ClosetheGap. We are almost there! Thanks to @donna_hoyne and @ACRKamilah for your support!
— Victoria Shanmugam (@VickiShanmugam) October 24, 2019
5
Here’s the handout we created to help rheumatologists guide pregnancy planning for women with lupus. https://t.co/E0AkHk0jha@LupusPregnancy. #acr19
— Megan Clowse (@drbags71) November 9, 2019
4
Immunosuppressive meds safe in pregnancy#ACR19 @rheumnow 3S017 pic.twitter.com/BNqGLixm9j
— Dr Irwin Lim (@_connectedcare) November 10, 2019
3
One thing that really impressed me from RITAZAREM (ritux vs azathioprine maintenance following ritux induction in AAV) apart from fewer relapses with ritux, is how well it was tolerated. Not even a hypogammaglob signal! #ACR19 ABST0806 @RheumNow pic.twitter.com/9l1jqlX0jg
— David Liew (@drdavidliew) November 10, 2019
2
GiACTA (phase 3 RCT) 2-year extension: 42% (n=25) of patients with giant cell arteritis in clinical remission and on no treatment after 1 year of weekly tocilizumab maintained treatment-free remission for another 2 years – John Stone #ACR19 #plenary #vasculitis
— NatRevRheumatol (@NatRevRheumatol) November 10, 2019
1
All the NEW Clinical Practice Guidelines for GOUT!
1. Allopurinol is 1st line
2. Start ULT during flare!
3. No tx for asymptomatic hyperuricemiaSeems pretty reasonable – surprised no rec for MTX w/pegloticase#ACR19 @RheumNow Thank you to @philipcrobinson for posting slides! pic.twitter.com/riwHGYNZ8T
— Mike Putman (@EBRheum) November 13, 2019
